geron nasdaqgern issues earnings results

Geron is a biotech company focused on telomerase inhibitor imetelstat for hematologic malignancies. The earnings beat and revenue growth are company-specific; no direct commodity or supply-chain impact. Commercial mechanism is weak: revenue guidance and trial progress affect Geron's valuation but do not create scarcity or margin squeeze in any broader sector. (not specified)